Inventor · disambiguated record
Roger Nitsch
Also filed as: NITSCH ROGER · NITSCH ROGER M
32 granted patents·38 pending applications·314 citations·filing 1994–2024
97Inventor score
Files withBIOGEN INT NEUROSCIENCE GMBH11UNIV ZUERICH11NITSCH ROGER5MASSACHUSETTS INST TECHNOLOGY4NEURIMMUNE HOLDING AG4
Top patents by PatentIndex Score
70 records- 0195US9828420B2Method of providing disease-specific binding molecules and targetsUNIV ZUERICH·Filed 2016·Granted Nov 28, 2017·14 cites·22 claims
- 0294US8940272B2Human anti-tau antibodiesNITSCH ROGER·Filed 2011·Granted Jan 27, 2015·31 cites·9 claims
- 0393US8940276B2Human anti-alpha-synuclein antibodiesWEIHOFEN ANDREAS·Filed 2009·Granted Jan 27, 2015·29 cites·26 claims
- 0492US10202445B2Method of providing disease-specific binding molecules and targetsUNIV ZUERICH·Filed 2017·Granted Feb 12, 2019·7 cites·13 claims
- 0591US10131708B2Methods of treating Alzheimer's diseaseUNIV OF ZUERICH·Filed 2017·Granted Nov 20, 2018·12 cites·88 claims
- 0691US8906367B2Method of providing disease-specific binding molecules and targetsNITSCH ROGER·Filed 2008·Granted Dec 9, 2014·29 cites·21 claims
- 0790US9896504B2Human anti-alpha-synuclein antibodiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2016·Granted Feb 20, 2018·8 cites·75 claims
- 0890US9605059B2Human anti-tau antibodiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2014·Granted Mar 28, 2017·12 cites·70 claims
- 0989US10874725B2Method of providing patient specific immune response in amyloidoses and protein aggregation disordersUNIV NEW YORK·Filed 2017·Granted Dec 29, 2020·4 cites·19 claims
- 1089US9670272B2Method of providing disease-specific binding molecules and targetsUNIV OF ZÜRICH·Filed 2012·Granted Jun 6, 2017·14 cites·10 claims
- 1189US9580493B2Anti-α synuclein binding moleculesWEIHOFEN ANDREAS·Filed 2012·Granted Feb 28, 2017·16 cites·58 claims
- 1286US10259866B2TDP-43 specific binding moleculesBIOGEN INT NEUROSCIENCE GMBH·Filed 2016·Granted Apr 16, 2019·7 cites·88 claims
- 1385US10301381B2Anti-alpha synuclein binding moleculesBIOGEN INT NEUROSCIENCE GMBH·Filed 2018·Granted May 28, 2019·4 cites·16 claims
- 1485US2024254256A1Human Anti-SOD1 AntibodiesNEURIMMUNE HOLDING AG·Filed 2024·Application pending·0 cites
- 1584US9975947B2Anti-alpha synuclein binding moleculesBIOGEN INT NEUROSCIENCE GMBH·Filed 2017·Granted May 22, 2018·4 cites·15 claims
- 1684US9587014B2TDP-43 specific binding moleculesBIOGEN INT NEUROSCIENCE GMBH·Filed 2012·Granted Mar 7, 2017·7 cites·33 claims
- 1781US9370531B2Method of providing patient specific immune response in amyloidoses and protein aggregation disordersHENCO KARSTEN·Filed 2008·Granted Jun 21, 2016·6 cites·11 claims
- 1879US9283271B2Human anti-SOD1 antibodiesMONTRASIO FABIO·Filed 2011·Granted Mar 15, 2016·5 cites·21 claims
- 1979US8323647B2Humanized antibodies against the β-amyloid peptideEWERT STEFAN·Filed 2008·Granted Dec 4, 2012·5 cites·39 claims
- 2077US8022268B2Transgenic animal model for alzheimer's diseaseUNIV ZUERICH·Filed 2008·Granted Sep 20, 2011·5 cites·3 claims
- 2177US6573276B2Muscarinic M1 agonist as an inhibitor of beta-amyloid (Aβ40 and Aβ42)-synthesisBOEHRINGER INGELHEIM PHARMA·Filed 2002·Granted Jun 3, 2003·10 cites·13 claims
- 2277US2022267471A1Human Anti-SOD1 AntibodiesNEURIMMUNE HOLDING AG·Filed 2022·Application pending·0 cites
- 2377US2022403011A1Method of providing disease-specific binding molecules and targetsUNIV OF ZUERICH·Filed 2022·Application pending·0 cites
- 2473US2021238265A1Human Anti-Tau AntibodiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2020·Application pending·0 cites
- 2572US5631168AAntemortem diagnostic test for Alzheimer's diseaseMASSACHUSETTS INST TECHNOLOGY·Filed 1994·Granted May 20, 1997·30 cites·15 claims
- 2671US11352441B2Human anti-SOD1 antibodiesNEURIMMUNE HOLDING AG·Filed 2019·Granted Jun 7, 2022·0 cites·14 claims
- 2771US10344097B2Human anti-SOD1 antibodiesNEURIMMUNE HOLDING AG·Filed 2016·Granted Jul 9, 2019·1 cites·11 claims
- 2870US2025213538A1Compounds and methods for use in the treatment of microglia-mediated disordersNSC THERAPEUTICS GMBH·Filed 2024·Application pending·0 cites
- 2970US2019153082A1Method of providing disease-specific binding molecules and targetsUNIV ZUERICH·Filed 2018·Application pending·0 cites
- 3069US11091540B2TDP-43 specific binding moleculesBIOGEN INT NEUROSCIENCE GMBH·Filed 2019·Granted Aug 17, 2021·0 cites·31 claims
- 3169US10703808B2Human anti-alpha-synuclein antibodiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2018·Granted Jul 7, 2020·0 cites·19 claims
- 3266US2021361754A1Method of providing patient specific immune response in amyloidoses and protein aggregation disordersUNIV NEW YORK·Filed 2020·Application pending·0 cites
- 3366US2019263896A1Method of providing disease-specific binding molecules and targetsUNIV OF ZUERICH·Filed 2018·Application pending·0 cites
- 3465US2015147343A1Method of providing disease-specific binding molecules and targetsNITSCH ROGER·Filed 2014·Application pending·0 cites
- 3564US5545566AAntemortem diagnostic test for alzheimer's diseaseMASSACHUSETTS INST TECHNOLOGY·Filed 1995·Granted Aug 13, 1996·28 cites·9 claims
- 3664US2013266585A1Method of Providing Disease-Specific Binding Molecules and TargetsUNIV ZUERICH·Filed 2013·Application pending·0 cites
- 3764US2013266586A1Method of Providing Disease-Specific Binding Molecules and TargetsUNIV ZUERICH·Filed 2013·Application pending·0 cites
- 3864US2013266514A1Method of Providing Disease-Specific Binding Molecules and TargetsUNIV ZUERICH·Filed 2013·Application pending·0 cites
- 3963US2019233506A1Human Anti-Tau AntibodiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2018·Application pending·0 cites
- 4061US12201619B2Compounds and methods for use in the treatment of microglia-mediated disordersNSC THERAPEUTICS GMBH·Filed 2019·Granted Jan 21, 2025·0 cites·15 claims
- 4161US7550648B2Inducing neurofibrillary tangles in transgenic mice expressing a mutant tau proteinUNIV ZUERICH·Filed 2007·Granted Jun 23, 2009·0 cites·24 claims
- 4258US2018002409A1Human Anti-Tau AntibodiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2017·Application pending·0 cites
- 4357US5962463AMethods of stimulating non-amyloidogenic processing of the amyloid precursor proteinMASSACHUSETTS INST TECHNOLOGY·Filed 1997·Granted Oct 5, 1999·18 cites·29 claims
- 4456US8519106B2Monoclonal human tumor-specific antibodyESSLINGER CHRISTOPH·Filed 2008·Granted Aug 27, 2013·1 cites·14 claims
- 4556US2006142194A1Methods and compounds for treating brain amyloidosisUNIV ZUERICH·Filed 2005·Application pending·0 cites
- 4654US2005015819A1Method of inducing the formation of neurofibrillary tangles in transgenic animalsFiled 2002·Application pending·0 cites
- 4754US2023242624A1HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)NEURIMMUNE AG·Filed 2021·Application pending·0 cites
- 4853US9273126B2Humanized antibodies against the beta-amyloid peptideEWERT STEFAN·Filed 2012·Granted Mar 1, 2016·0 cites·9 claims
- 4953US2011182809A1Method of Promoting NeurogenesisUNIV ZUERICH·Filed 2009·Application pending·0 cites
- 5053US2005239169A1Methods of diagnosing or treating neurological diseases and cell degenerationROGER NITSCH·Filed 2004·Application pending·0 cites
Showing the top 50 of 70 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Roger Nitsch files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →